256 related articles for article (PubMed ID: 28956034)
21. Serum metabolomics detected by LDI-TOF-MS can be used to distinguish between diabetic patients with and without diabetic kidney disease.
Qian F; Zhao L; Zhang D; Yu M; Zhou W; Jin J
FEBS Open Bio; 2023 Oct; 13(10):1844-1858. PubMed ID: 37525631
[TBL] [Abstract][Full Text] [Related]
22. Serum high mobility group box 1 as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes.
Liu T; Zhao H; Wang Y; Qu P; Wang Y; Wu X; Zhao T; Yang L; Mao H; Peng L; Zhan Y; Li P
Front Immunol; 2024; 15():1334109. PubMed ID: 38481996
[TBL] [Abstract][Full Text] [Related]
23. Elevated serum level of pancreatic stone protein/regenerating protein (PSP/reg) is observed in diabetic kidney disease.
Li L; Jia D; Graf R; Yang J
Oncotarget; 2017 Jun; 8(24):38145-38151. PubMed ID: 28418911
[TBL] [Abstract][Full Text] [Related]
24. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease.
Sharma K; Karl B; Mathew AV; Gangoiti JA; Wassel CL; Saito R; Pu M; Sharma S; You YH; Wang L; Diamond-Stanic M; Lindenmeyer MT; Forsblom C; Wu W; Ix JH; Ideker T; Kopp JB; Nigam SK; Cohen CD; Groop PH; Barshop BA; Natarajan L; Nyhan WL; Naviaux RK
J Am Soc Nephrol; 2013 Nov; 24(11):1901-12. PubMed ID: 23949796
[TBL] [Abstract][Full Text] [Related]
25. Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer.
Darshi M; Van Espen B; Sharma K
Am J Nephrol; 2016; 44(2):92-103. PubMed ID: 27410520
[TBL] [Abstract][Full Text] [Related]
26. Comparison of plasma and erythrocyte membrane fatty acid compositions in patients with end-stage renal disease and type 2 diabetes mellitus.
Sertoglu E; Kurt I; Tapan S; Uyanik M; Serdar MA; Kayadibi H; El-Fawaeir S
Chem Phys Lipids; 2014 Feb; 178():11-7. PubMed ID: 24384240
[TBL] [Abstract][Full Text] [Related]
27. Metabolomic profiling of amino acids study reveals a distinct diagnostic model for diabetic kidney disease.
Wang J; Zhou C; Zhang Q; Liu Z
Amino Acids; 2023 Nov; 55(11):1563-1572. PubMed ID: 37736814
[TBL] [Abstract][Full Text] [Related]
28. Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians.
Afshinnia F; Nair V; Lin J; Rajendiran TM; Soni T; Byun J; Sharma K; Fort PE; Gardner TW; Looker HC; Nelson RG; Brosius FC; Feldman EL; Michailidis G; Kretzler M; Pennathur S
JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31573977
[TBL] [Abstract][Full Text] [Related]
29. Lipin-1 deficiency deteriorates defect of fatty acid β-oxidation and lipid-related kidney damage in diabetic kidney disease.
Lin S; Wang L; Jia Y; Sun Y; Qiao P; Quan Y; Liu J; Hu H; Yang B; Zhou H
Transl Res; 2024 Apr; 266():1-15. PubMed ID: 37433392
[TBL] [Abstract][Full Text] [Related]
30. Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease.
Hasegawa S; Inagi R
Curr Diab Rep; 2021 May; 21(7):21. PubMed ID: 33974145
[TBL] [Abstract][Full Text] [Related]
31. Baicalin ameliorates renal fibrosis by upregulating CPT1α-mediated fatty acid oxidation in diabetic kidney disease.
Hu H; Li W; Hao Y; Peng Z; Zou Z; Liang W
Phytomedicine; 2024 Jan; 122():155162. PubMed ID: 37922789
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease.
Cleveland KH; Schnellmann RG
Pharmacol Rev; 2023 Mar; 75(2):250-262. PubMed ID: 36781216
[TBL] [Abstract][Full Text] [Related]
33. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease.
Pereira PR; Carrageta DF; Oliveira PF; Rodrigues A; Alves MG; Monteiro MP
Med Res Rev; 2022 Jul; 42(4):1518-1544. PubMed ID: 35274315
[TBL] [Abstract][Full Text] [Related]
34. High-expression of FABP4 in Tubules is a Risk Factor for Poor Prognosis in DKD Patients.
Huang Y; Cui X; Li Z; Yuan S; Han Y; Xu X; Fu X; Shi K; Zhang Z; Wei J; Xia S; Xiao Y; Xue S; Sun L; Liu H; Zhu X
Curr Med Chem; 2024; 31(22):3436-3446. PubMed ID: 38299395
[TBL] [Abstract][Full Text] [Related]
35. Current updates on metabolites and its interlinked pathways as biomarkers for diabetic kidney disease: A systematic review.
Das S; Devi Rajeswari V; Venkatraman G; Elumalai R; Dhanasekaran S; Ramanathan G
Transl Res; 2024 Mar; 265():71-87. PubMed ID: 37952771
[TBL] [Abstract][Full Text] [Related]
36. Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease.
Liu JJ; Ghosh S; Kovalik JP; Ching J; Choi HW; Tavintharan S; Ong CN; Sum CF; Summers SA; Tai ES; Lim SC
Kidney Int Rep; 2017 May; 2(3):470-480. PubMed ID: 29142974
[TBL] [Abstract][Full Text] [Related]
37. CD36 deletion ameliorates diabetic kidney disease by restoring fatty acid oxidation and improving mitochondrial function.
Niu H; Ren X; Tan E; Wan X; Wang Y; Shi H; Hou Y; Wang L
Ren Fail; 2023; 45(2):2292753. PubMed ID: 38097943
[TBL] [Abstract][Full Text] [Related]
38. Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population.
Yan D; Tu Y; Jiang F; Wang J; Zhang R; Sun X; Wang T; Wang S; Bao Y; Hu C; Jia W
PLoS One; 2015; 10(6):e0129797. PubMed ID: 26029914
[TBL] [Abstract][Full Text] [Related]
39. Serum integrative omics reveals the landscape of human diabetic kidney disease.
Liu S; Gui Y; Wang MS; Zhang L; Xu T; Pan Y; Zhang K; Yu Y; Xiao L; Qiao Y; Bonin C; Hargis G; Huan T; Yu Y; Tao J; Zhang R; Kreutzer DL; Zhou Y; Tian XJ; Wang Y; Fu H; An X; Liu S; Zhou D
Mol Metab; 2021 Dec; 54():101367. PubMed ID: 34737094
[TBL] [Abstract][Full Text] [Related]
40. The impact of mitochondrial quality control by Sirtuins on the treatment of type 2 diabetes and diabetic kidney disease.
Xu J; Kitada M; Koya D
Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165756. PubMed ID: 32147421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
